Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation

被引:10
作者
Yoon, Jae-Ho [1 ]
Lee, Seok [1 ]
Kim, Hee-Je [1 ]
Lee, Jong-Wook [1 ]
Min, Woo-Sung [1 ]
Chung, Byung Ha [2 ]
Yang, Chul Woo [2 ]
Kim, Yong-Soo [2 ]
Kim, Ji-Il [3 ]
Moon, In Sung [3 ]
Oh, Eun Ji [4 ]
Park, Gyeong-Sin [5 ]
Cho, Seok-Goo [1 ]
机构
[1] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Blood & Marrow Transplantat Ctr, Dept Hematol, Seoul 137701, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Nephrol, Seoul 137701, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea
[4] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Lab Med, Seoul 137701, South Korea
[5] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Pathol, Seoul 137701, South Korea
关键词
hematopoietic stem cell transplantation; kidney transplantation; post-transplant lymphoproliferative disorder; prognosis; SOLID-ORGAN TRANSPLANTATION; PROGNOSTIC-FACTORS; RITUXIMAB; RECIPIENTS; LYMPHOMAS; PTLD; IMMUNOSUPPRESSION; SURVIVAL; DISEASE;
D O I
10.1111/tri.12328
中图分类号
R61 [外科手术学];
学科分类号
摘要
Post-transplant lymphoproliferative disorder (PTLD) is a major complication caused by immune-suppression after transplantation. Survival outcome is known to be poor and the characteristics are not fully understood because of its rare incidence. This single center retrospective study enrolled 41 adult PTLD patients after kidney-transplantation (KT, n=28) and hematopoietic stem cell transplantation (HSCT, n=13) from 1992 to 2012. We compared the characteristics and estimated the survival outcomes according to several factors [age-adjusted-IPI (aaIPI), pathologic subtype, viral status, extranodal manifestation] and added some significant parameters to aaIPI scoring system. Post-HSCT-PTLD patients were younger and showed earlier onset, and viral status was more frequently identified. Ten-year OS of the entire group was 44% but the 10-year OS was not significantly different between post-KT-PTLD and post-HSCT-PTLD (39% vs. 56%, P=0.860). The time onset of PTLD and viral statuses were not meaningful, however, aaIPI, age>50, extranodal manifestation and monomorphic subtype were predictive for OS. We used those factors for PTLD-specific scoring which showed intermediate-risk (HR=7.1, P=0.019) and high-risk (HR=16.5, P=0.001) presented worse OS compared to low-risk subgroup. Although the treatment strategies were heterogenous, this study showed comprehensive PTLD data between KT versus HSCT, and our PTLD-specific scoring might be validated by another larger studies.
引用
收藏
页码:721 / 732
页数:12
相关论文
共 50 条
  • [21] Lymphoproliferative disorder in a twin female teenager post kidney transplantation
    Isac, Raluca
    Costa, Rodica
    Lazureanu, Dorela Codruta
    Olariu, Cristina-Ioana
    Muntean, Adriana Milena
    Aldea, Cornel Olimpiu
    Doros, Gabriela Simona
    Gafencu, Mihai
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (03) : 1041 - 1045
  • [22] Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation
    Hideaki Ohta
    Norihide Fukushima
    Keiichi Ozono
    International Journal of Hematology, 2009, 90 : 127 - 136
  • [23] Post-transplant lymphoproliferative disorder after paediatric liver transplantation
    Liu, Ying
    Sun, Li-Ying
    Zhu, Zhi-jun
    Wei, Lin
    Qu, Wei
    Wang, Lin
    Yuan, Lei-lei
    Zeng, Zhi-Gui
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (04)
  • [24] Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation
    Kopinska, Anna
    Helbig, Grzegorz
    Frankiewicz, Andrzej
    Grygoruk-Wisniowska, Iwona
    Kyrcz-Krzemien, Slawomira
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (03): : 215 - 217
  • [25] Lymphoproliferative disorder after kidney transplantation
    Petrovic, Lada
    Durdevic-Mirkovic, Tatjana
    Mitic, Igor
    Bozic, Dusan
    Urosevic, Ivana
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2018, 146 (1-2) : 81 - 85
  • [26] Severe post-transplant lymphoproliferative disorder after living donor liver transplantation
    Kuramitsu, Kaori
    Fukumoto, Takumi
    Fukushima, Kenji
    Iwasaki, Takeshi
    Tominaga, Masahiro
    Matsui, Toshimitsu
    Kawakami, Fumi
    Itoh, Tomoo
    Ku, Yonson
    HEPATOLOGY RESEARCH, 2015, 45 (03) : 356 - 362
  • [27] Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
    Clerico, Michele
    Dogliotti, Irene
    Aroldi, Andrea
    Consoli, Chiara
    Giaccone, Luisa
    Bruno, Benedetto
    Cavallo, Federica
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (24)
  • [28] Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient
    Lones, MA
    Kirov, I
    Said, JW
    Shintaku, IP
    Neudorf, S
    BONE MARROW TRANSPLANTATION, 2000, 26 (09) : 1021 - 1024
  • [29] Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient
    MA Lones
    I Kirov
    JW Said
    IP Shintaku
    S Neudorf
    Bone Marrow Transplantation, 2000, 26 : 1021 - 1024
  • [30] Peritoneal lymphomatosis as a rare entity of post-transplant lymphoproliferative disorder after kidney transplantation: a case report
    Shirai, Kana
    Ogata, Masatomo
    Murata-Hasegawa, Marie
    Miyauchi, Masataka
    Sakurai, Yuko
    Shinoda, Kazunobu
    Koike, Junki
    Shibagaki, Yugo
    Yazawa, Masahiko
    CEN CASE REPORTS, 2025,